Merck/Schering-Plough Initiate Vytorin Acute Coronary Syndrome Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The two-year, 10,000-patient IMPROVE IT study will evaluate the Zetia/Zocor combination's morbidity/mortality risk reduction compared to Zocor alone. The trial will compare Vytorin 10 mg/40 mg to Zocor 40 mg in patients with acute coronary syndrome.